Law360, New York (December 14, 2011, 7:22 PM ET) -- When Amylin Pharmaceuticals Inc.'s joint marketing agreement for a diabetes drug with Eli Lilly & Co. went sour this spring, the parties' lawyers devised a unique solution: They terminated the collaborative effort on a successful drug and returned the rights to Amylin through a $1.2 billion revenue sharing deal.
In an industry full of small companies in need of funding to develop new products, joint ventures like Amylin and Eli Lilly's deal for Type 2 diabetes drug Byetta are common and often short-lived, but they usually...
Sealing The Deal: Skadden Splits Diabetes Drug Alliance
To view the full article, take a free trial now.
